Forxiga (Dapagliflozin) in Kenya

Overview

Forxiga is a SGLT2 inhibitor containing dapagliflozin, used to treat Type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD). It lowers blood glucose by promoting urinary glucose excretion and provides cardio-renal protection. Available as 10mg tablets, it requires prescription and monitoring.

Composition

• Active Ingredient: Dapagliflozin 10mg per tablet.
• Form: Yellow, diamond-shaped, film-coated tablets.
• Inactive Ingredients: Microcrystalline cellulose, lactose, magnesium stearate.

Side Effects

Common

• Genital Infections: Vaginal yeast infections, balanitis (due to glucosuria).
• Urinary Tract Infections (UTIs): Dysuria, increased frequency.
• Volume Depletion: Dizziness, hypotension (especially in elderly/renal impairment).
• Ketoacidosis: Rare but serious (even in T2DM; monitor for nausea/vomiting).

Serious Risks

• Acute Kidney Injury (AKI): Especially with dehydration or nephrotoxic drugs.
• Diabetic Ketoacidosis (DKA): Euglycemic DKA possible (check ketones if symptomatic).
• Necrotizing Fasciitis: Fournier’s gangrene (rare; requires immediate surgery).
• Hypoglycemia: Risk increases with insulin/sulfonylureas.

How to Use

• Dosage:
  • T2DM: 10mg once daily (with or without food).
  • HF/CKD: 10mg once daily (irrespective of diabetes status).
• Administration:
  • Take in the morning to reduce nocturia.
  • Swallow whole; do not crush/chew.
• Monitoring:
  • Renal Function: eGFR at baseline, then every 3–6 months.
  • Volume Status: Assess for dehydration (especially in elderly).
  • Ketones: Check if nausea/vomiting occurs.
• Precautions:
  • Avoid if eGFR <30 mL/min (contraindicated in severe CKD).
  • Discontinue if hospitalized for acute illness/surgery (DKA risk).
  • Hydration: Maintain fluid intake to prevent AKI.

Frequently Asked Questions

1. Is Forxiga available over-the-counter?
   No – prescription-only by endocrinologists or physicians.

2. Does NHIF cover it?
   Partially – covered for T2DM under chronic illness scheme (co-payment required). Not covered for HF/CKD.

3. Can it be used for Type 1 diabetes?
   No – not approved; DKA risk is higher.

4. What if I miss a dose?
   Take when remembered unless near next dose. Never double-dose.

5. Are there cheaper alternatives?
   Yes – empagliflozin (Jardiance) costs KES 6,000–10,000/month.

6. Is it safe during pregnancy?
   No – discontinue if pregnancy occurs (potential fetal harm).

7. How long does one pack last?
   30 days (10mg daily).

Conclusion

Forxiga is a first-line therapy for T2DM with established CVD, HF, or CKD in Kenya, offering significant cardio-renal benefits beyond glucose control. Its once-daily dosing and weight loss advantage improve adherence, but cost (KES 8,000–12,000/month) and limited NHIF coverage restrict access. Patients must prioritize hydration, renal monitoring, and infection prevention. While not curative, it reduces hospitalizations and mortality in high-risk groups. For resource-limited settings, generic SGLT2 inhibitors (e.g., empagliflozin) may offer affordability. Early initiation in eligible patients can transform outcomes, especially where cardiovascular/renal complications drive diabetes morbidity.